Relapsed B cell precursor Acute lymphoblastic leukemia
Also known as: Relapsed B-cell precursor Acute Lymphoblastic Anemia
Drug | Drug Name | Drug Description |
---|---|---|
DB09052 | Blinatumomab | An antineoplastic antibody used to treat CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients, as well as those in first or second complete remission with minimal residual disease (MRD). |
DB15699 | Brexucabtagene autoleucel | A modified autologous chimeric antigen receptor (CAR) T cell therapy employing a modified murine anti-CD19 single-chain variable fragment linked to CD28 and CD3ΞΆ co-stimulatory domains for the treatment of patients with relapsed and refractory mantle cell lymphoma. |
DB05889 | Inotuzumab ozogamicin | An antibody-drug conjugate used to treat B-cell precursor acute lymphoblastic leukemia (ALL). |
DB13881 | Tisagenlecleucel | A CAR T cell therapy for relapsed or refractory large B-cell lymphoma and diffuse large B-cell lymphoma. |
Drug | Drug Name | Phase | Status | Count |
---|